Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
Ir J Med Sci
; 190(1): 403-409, 2021 Feb.
Article
en En
| MEDLINE
| ID: mdl-32627127
ABSTRACT
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for coronavirus disease 19 (COVID-19), has rapidly spread since December 2019 to become the focus of healthcare systems worldwide. Its highly contagious nature and significant mortality has led to its prioritization as a public health issue. The race to prevent and treat this disease has led to "off-label" prescribing of medications such as hydroxychloroquine, azithromycin, and Kaletra (lopinavir/ritonavir). Currently, there is no robust clinical evidence for the use of these drugs in the treatment of COVID-19, with most, if not all of these medications associated with the potential for QT interval prolongation, torsades de pointes, and resultant drug-induced sudden cardiac death. The aim of this document is to help healthcare providers mitigate the potential deleterious effects of drug-induced QTc prolongation.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
/
2_ODS3
/
4_TD
/
6_ODS3_enfermedades_notrasmisibles
Problema de salud:
1_doencas_nao_transmissiveis
/
2_muertes_prematuras_enfermedades_notrasmisibles
/
4_covid_19
/
6_cardiovascular_diseases
/
6_congenital_chromosomal_anomalies
Asunto principal:
Antivirales
/
Síndrome de QT Prolongado
/
Torsades de Pointes
/
Azitromicina
/
Ritonavir
/
Lopinavir
/
Tratamiento Farmacológico de COVID-19
/
Hidroxicloroquina
/
Antibacterianos
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
/
Guideline
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Ir J Med Sci
Año:
2021
Tipo del documento:
Article
País de afiliación:
Irlanda